Phathom earmarks Celgene exec as next CEO

4 October 2019

Phathom Pharmaceuticals has announced that Terrie Curran will be appointed chief executive effective upon the closing of the acquisition of Celgene Corp (Nasdaq: CELG) by Bristol-Myers Squibb (NYSE: BMS). She has also been appointed to Phathom’s board of directors.

Ms Curran will succeed David Socks as part of a planned transition. Mr Socks will continue to serve as chief executive until Ms Curran joins and will then serve as interim Chief Financial Officer and continue to serve as a member of the Board. Phathom also announced the appointments of Michael Cola, Heidi Kunz, and Chris Slavinsky as members of the board.

Phathom Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders, was set up in May this year, by Japan’s leading drugmaker Takeda (TYO: 4502) under a collaboration with Frazier Healthcare Partners

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK